A global consensus meeting was convened to go over current evidence and knowledge gaps and propose collaborative studies on population-wide screening and eradication of Helicobacter pylori for the prevention of gastric cancer (GC).
Prescription of Helicobacter pylori eradication therapy within 1 year of gastric cancer treatment reduces the risk of later metachronous lesion development.
Certain enteric pathogens are associated with higher risk of incident inflammatory bowel disease, while others are could be protective.
A novel rifabutin-based triple therapy (RHB-105) is effective for eradication of Helicobacter pylori, with eradication rates unaffected by resistance to clarithromycin or metronidazole.
A novel rifabutin-based therapy (RHB-105) may be a potential first-line defense against Helicobacter pylori (H. pylori) infection.
The American Gastroenterological Association recently published new clinical practice guidelines on the management of gastric intestinal metaplasia.
This study follows up to examine the implementation of a 14-day quadruple nonbismuth concomitant regimen to treat Helicobacter pylori, as proposed by recent Guidelines and Consensus Statements.
The prevalence of H pylori infection continues to fall in the general population with only 16% of all gastric and 25% of all duodenal patients with ulcer harboring H pylori.
Dual therapy with vonoprazan and low-dose amoxicillin had similar efficacy to triple-drug treatment for the eradication of Helicobacter pylori.
Individuals who are racial or ethnic minorities and individuals who are smokers experience significantly higher risks for gastric cancer following a diagnosis of Helicobacter pylori infection.
Only complete eradication of Helicobacter pylori infection, not treatment alone, will reduce the risk for developing stomach cancer.
The FDA has approved Talicia (omeprazole magnesium, amoxicillin and rifabutin delayed-release capsules; RedHill Biopharma) for the treatment of Helicobacter pylori (H. pylori) infection in adults.
The researchers discovered significant differences and substantial heterogeneity in risk for GC among API subgroups. Substantial differences in all-cause survival among API subgroups were also observed.
The study researchers concluded that recommendations for Helicobacter pylori screening should also include patients who exhibit GERD symptoms only, irrespective of regional origin.
A recent review published in the journal Pharmacotherapy summarizes recommendations for the treatment of Helicobacter pylori infection in special patient populations.
Reductions in gastric cancer mortality seen with H. pylori treatment, vitamin, garlic supplementation.
The impact of eradicated Helicobacter pylori on the pediatric gastric microbial community structure shows restoration of bacterial diversity consistent with noninfected children in the same endemic region.
Type 2 diabetes was linked to an increased risk for gastric cancer (adjusted hazard ratio, 1.73). Stratified statistical analysis demonstrated a significantly higher risk for gastric cardia cancer (adjusted hazard ratio, 3.40) and a significantly increased risk in those with suboptimal glycemic control (adjusted hazard ratio, 1.68).